Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ: THAR )

3.741 UNCHANGED
Streaming Delayed Price Updated: 3:42 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.741
Bid (Size) 3.500 (2)
Ask (Size) 4.840 (2)
Prev. Close 3.741
Today's Range 3.741 - 3.741
52wk Range 2.750 - 142.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Via ACCESSWIRE

Performance

YTD
-50.61%
-50.61%
1 Month
+32.65%
+32.65%
3 Month
-32.67%
-32.67%
6 Month
-36.29%
-36.29%
1 Year
-95.47%
-95.47%

More News

Read More
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Tharimmune (THAR) Shares Are Moving
Via Benzinga
THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
Via InvestorPlace
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Via ACCESSWIRE
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Tharimmune (THAR) Shares Are Getting Hammered
Via Benzinga
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune to Present at 2024 BIO International Convention
Via ACCESSWIRE
Why Is Verastem (VSTM) Stock Down 62% Today?
Via InvestorPlace
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
Via InvestorPlace
Why Is Tharimmune (THAR) Stock Moving Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Tharimmune Announces 1-for-15 Reverse Stock Split
Via ACCESSWIRE
Tharimmune, Inc. (NASDAQ: THAR) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Via ACCESSWIRE
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Via ACCESSWIRE
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Via ACCESSWIRE
Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.